Artificial intelligence continues to redefine clinical development yet much of the conversation remains driven by hype rather than hard evidence. At the upcoming PCMG AI Symposium 2025, Volv Global helps lead a programme dedicated to separating real world value from overpromised innovation.

The event, hosted at the Royal Society of Medicine in London, focuses on AI transparency, validation, and evidence-based adoption in clinical trials. Through case studies and expert led sessions, the symposium empowers sponsors, CROs, and procurement leaders to evaluate AI tools based on scientific rigour and measurable outcomes.

 

Volv Global is proud to be supporting the organisation of the upcoming PCMG AI Symposium on AI in Clinical Trials, shaping a programme designed to move the conversation from buzzwords to real-world impact.

The healthcare industry has already invested heavily in AI, but clear results remain scarce. Too often, solutions are presented as “black boxes,” making it difficult to judge reliability, spot bias, or compare offerings on a fair basis. This lack of clarity creates real problems: how can stakeholders separate genuine innovation from overpromised claims, or ensure that AI tools align with long-term strategy and compliance requirements? With fragmented data and uneven evidence standards, procurement decisions risk being made on persuasion rather than proof.

This event has been structured to counter those challenges head-on. Using a strengths-weaknesses-opportunities-threats approach, the programme highlights both proven successes and lessons from when AI has fallen short. Volv’s contribution reflects our own philosophy – scientific rigour, transparency, and practical guidance – ensuring participants leave with a realistic framework for evaluating AI in clinical trials.

 

Volv Global involvement

• Opening keynote: The Future of AI in Pharma – Get Ready To Ride The Next Wave! by Volv Global founder and CEO Christopher Rudolf
  AI has promised to transform clinical development – yet most projects still fail to deliver. Too often, they “pave the cow path,” repeating old processes with new technology. With billions invested and limited clear results, the question remains: how do we separate genuine progress from overpromised potential?
  Christopher will share insights from the leading edge of AI in healthcare, explaining why 85% of AI projects fail, what it takes to turn proof-of-concept into real-world impact, and why success depends as much on collaboration, trust, and adaptability as it does on data and algorithms.
• Session moderation: Maximising AI Potential: Lessons from Real-World Experience by Volv Global Clinical Innovation Director Léon Van Wouwe
• Opening and closing remarks by Tim Hardman, Managing Director, Niche Science & Technology, and Volv Global Clinical Innovation Director Léon Van Wouwe.

 

PCMG AI Symposium 2025

• AI tools in clinical trials offer the potential for faster timelines, reduced costs, and more efficient operations. But alongside genuine breakthroughs come questions about how, and where, these tools truly deliver.This in-person symposium takes a clear-eyed look at AI in clinical development, exploring both the opportunities and the challenges. Designed for sponsor companies, CROs, service providers, and procurement leaders, it will equip attendees to assess AI solutions with confidence and make decisions grounded in evidence.Through case studies, expert panels, and a step-by-step procurement playbook, the programme will examine the spectrum from proven successes to lessons learned when technology falls short.
• November 24, 2025 – one-day, in-person only
• Royal Society of Medicine, London, UK
• Find out more about PCMG AI Symposium here: PCMG: Event Details

 

We look forward to welcoming you to this important discussion. If you would like to meet at the PCMG AI Symposium 2025, please Contact Us to book a meeting!

Looking forward to having great discussions with you there!

 

Key Takeaways

• PCMG AI Symposium 2025 addresses the real-world performance of AI tools in clinical trials.
• Volv Global co-organises the event, promoting transparency and scientific rigour.
• The programme features case studies, expert panels, and a procurement playbook.
• Objective: help the industry distinguish between proven value and overhyped AI claims.
• Event held November 24, 2025, at the Royal Society of Medicine, London.

 

Frequently Asked Questions

Q1: What is the PCMG AI Symposium 2025 about?
The symposium focuses on AI’s real-world role in clinical trials highlighting validated technologies and lessons from where AI has failed to deliver.

Q2: Who should attend this event?
Sponsors, CROs, procurement professionals, and clinical leaders seeking a deeper understanding of AI implementation in trial operations.

Q3: How is Volv Global involved?
Volv Global co-organises the symposium and contributes its expertise in AI validation, transparency, and ethical adoption within clinical settings.

Q4: Why is this event important now?
As AI adoption accelerates, the need for proven, compliant, and measurable solutions becomes critical to ensuring trust and sustainable impact.

Q5: When and where is the PCMG AI Symposium taking place?
November 24, 2025, at the Royal Society of Medicine, London, UK.